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INTRODUCTION
Establishment of a convenient and useful criteria based on
clinicopathologic information that can easily determine the out-
come of patients with gastric carcinoma could provide beneficial
information for both the patients and the physicians.
Lymph node metastasis can be a representative parameter
among the pathologic factors that predict tumor recurrence and
the prognosis of patients with malignant tumors, including gastric
carcinoma (1-3).
On the other hand, elevation of serum C-reactive protein, as
part of the inflammatory response against the tumor, has been
reported to be a useful predictor of the malignant potential of
gastrointestinal tumors, including gastric carcinoma (4, 5).
However, progression and invasion of human malignant tumors
can be influenced by the balance between the environmental condi-
tions around the tumors and the physical state of the tumor-
bearing patients.
In the current study, we developed a cumulative score, based on
both the incidence of pathologic lymph node metastasis and preop-
erative elevation of serum CRP, and investigated whether it could
provide a strict stratification of the prognosis of patients with
gastric carcinoma who had been treated with curative resection.
PATIENTS AND METHODS
Patients, collection of blood samples, and measurement of C-rea-
ctive protein (CRP). Three hundred and twenty patients with gastric
carcinoma, comprised of 222 men and 98 women who had been
treated by curative resection, defined as a standard distal or total
gastrectomy with a D1+ or D2 lymph node dissection, in our
institute between 1998 and 2012, were enrolled in this study.
Patients who had a history of malignant tumors in other organs or
had other chronic inflammatory diseases that could lead to eleva-
tion of serum CRP were excluded.
No neoadjuvant therapy was administered to the patients en-
rolled in this study.
All blood samples for serum CRP measurements were collected
just before the surgical procedure. Normal value of CRP was 1.0
mg/dL and then, patients who had serum CRP concentrations1.0
mg/dL were regarded as CRP positive.
This study was approved by the institutional ethic committee of
Fukuoka Higashi Medical Center.
Pathologic investigations. Pathologic factors were determined ac-
cording to the TNM classification of malignant tumours prescribed
by the International Union Against Cancer (6).
Definition of the cumulative score. Patients who had both elevated
serum CRP and pathologic lymph node metastasis were allocated a
Score of 2 and patients who had only one or neither were allocated
Scores of 1 or 0, respectively.
Follow-up of the patients. The patients were followed-up until
their death and only patients who died of gastric carcinoma were
included in the tumor-related deaths. The period from the opera-
tion to the date of death was defined as the survival time. The
follow-up interval after the operation ranged from 2 months to 9
years and 2 months.
Statistical analysis. All statistical analyses were performed using
StatView (SAS Institute Inc, Cary, NC). Chi -square test and t test
were used to compare the differences between values in each score
group. Survival curves were constructed using the Kaplan-Meier
method, and the Mantel -Cox test was used to analyze the equality of
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the survival curves. Cox proportional hazards model in a forward
stepwise manner was used in the multivariate analysis to deter-
mine the independent prognostic indicators. P values 0.05
were considered significant.
RESULTS
The correlations between the cumulative score and the clinico-
pathologic characteristics are shown in Table I. Significant differ-
ences were observed regarding the location of the tumor (P =
0.021), depth of the tumor (P0.0001), histological type (P =
0.0007), lymphatic invasion (P0.0001), venous invasion (P
0.0001), stage of the tumors (P0.0001), and the surgical resec-
tion procedure (P0.0001). Additionally, a significant correla-
tion of the cumulative score with carcinoembryonic antigen (CEA ;
Table, P = 0.004) and with carbohydrate antigen 19-9 (CA19-9 ;
Table, P0.0001) was observed. The 1-, 3 - and 5-year survival
rates of patients with a score of 0 were 100%, 100%, and 94.0%,
respectively. These survival rates were 90.1%, 75.8%, and 69.1%,
respectively, among patients with a score of 1, and 78.3%, 40.0%
and 26.6%, respectively, among patients with a score of 2. Signifi-
cant differences were observed between the survival of patients
with scores of 0 and 1 (P0.0001) and also between those with
scores of 1 and 2 (P0.0001, Figure. 1).
Table . Relationship between the cumulative score and clinicopa-
thologic factors of the patients




(n = 36) P
Sex
Male 116 (69.0) 76 (65.5) 30 (83.3) 0.127
Female 52 (31.0) 40 (34.5) 6 (16.7)
Age 67.311.1 69.210.7 70.19.8 0.136
Location of tumor
Upper 20 (11.9) 21 (18.1) 11 (30.6) 0.021
Middle 112 (66.7) 55 (47.4) 16 (44.4)
Lower 36 (21.4) 40 (34.5) 9 (25.0)
Depth of tumor
T1 127 (75.6) 15 (12.9) 0 0.0001
T2 16 (9.5) 19 (16.4) 4 (11.1)
T3 22 (13.1) 59 (50.9) 20 (55.6)
T4 3 (1.8) 23 (19.8) 12 (33.3)
Histology
Well or Moderately
101(60.1) 51 (44.0) 14 (38.9) 0.007
Poorly
67(39.9) 65 (56.0) 22 (61.1)
Lymphatic invasion
No 130 (77.4) 15 (12.9) 7 (19.4) 0.0001
Yes 38 (22.6) 101 (87.1) 29 (80.6)
Venous invasion
No 157 (93.5) 67 (57.8) 18 (50.0) 0.0001
Yes 11 (6.5) 49 (42.2) 18 (50.0)
Tumor stage
 143 (85.1) 13 (11.2) 0 0.0001
 25 (14.9) 44 (37.9) 9 (25.0)
 0 59 (50.9) 27 (75.0)
Surgical Procedure
Distal 133 (79.2) 74 (63.8) 12 (33.3) 0.0001
Total 35(20.8) 42(36.2) 24(66.7)
Well well differentiated adenocarcinoma, Moderately moderately differenti-
ated adenocarcinoma, Poorly poorly differentiated adenocarcinoma,
Distal distal gasterectomy, Total total gastrectomy.
Values in the parenthesis are the percentages
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Table . Relationship between the cumulative score and carbohy-

















Values in the parenthesis are the percentages
Fig. 1. Survival curves among whole patients.
Significant differences were observed between the survival of patients
with cumulative scores of 0 and 1 (P0.0001) and those patients with
cumulative scores of 1 and 2 (P0.0001).
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Analysis restricted to patients with stageorare shown in
Table. Significant differences were observed regarding the
depth of the tumor (P = 0.038), lymphatic invasion (P0.0001),
stage of the tumors (P0.0001), and the surgical resection proce-
dure (P = 0.013). Similarly, significant differences were observed
between the survival of patients with scores of 0 (with 5-year sur-
vival rate of 88.9%) and 1 (with 5-year survival rate of 61.4% ; P =
0.010) and also between those with scores of 1 and 2 (with 5-year
survival rate of 61.4% ; P = 0.0004, Figure. 2).
Multivariate analysis demonstrated that the cumulative score (P =
0.0003) and the depth of the tumor (P = 0.016) were independent
prognostic indicators (Table).
DISCUSSION
The most difficult and serious problem in the clinical treatment of
gastric carcinoma is that the subsequent outcome of the patients
could be desperate in cases of distant metastasis with detection of
the tumor and the tumor recurrence. While recurrent liver or lung
tumors derived from colorectal carcinoma are occasionally indi-
cated for surgical treatment followed by the systemic chemother-
apy under some restricted conditions, recurrent tumors metasta-
sized from gastric carcinoma are rarely subjected to surgical treat-
ment due to its small contribution to the prolongation of the sur-
vival (7, 8).
Therefore, in order to improve the prognosis of patients with
gastric carcinoma, more useful and convenient information to pre-
dict tumor recurrence and the prognosis of patients with gastric
carcinoma who have been treated with curative resection are
necessary.
In establishing more useful prognostic criteria to predict the out-
come of tumor-bearing disease that are both convenient and cost-
effective, laboratory and histological examinations might be used
for patients with malignant tumors. While all of the pathological
factors, including lymphatic permeation, venous invasion and lymph
node metastasis, are indicators that can predict the aggressiveness of
Table . Relationship between the cumulative score and clinicopa-
thologic factors of the patients with tumors of stageor




(n = 36) P
Sex
Male 14 (56.0) 66 (64.1) 30 (83.3) 0.470
Female 11 (44.0) 37 (35.9) 6 (16.7)
Age 66.211.2 69.310.9 70.19.8 0.251
Location of tumor
Upper 4 (16.0) 21 (20.4) 11 (30.6) 0.552
Middle 14 (56.0) 47 (45.6) 16 (44.4)
Lower 7 (28.0) 35 (34.0) 9 (25.0)
Depth of tumor
T1 0 5 (4.8) 0 0.038
T2 0 16 (15.5) 4 (11.1)
T3 22 (88.0) 59 (57.3) 20 (55.6)
T4 3 (12.0) 23 (22.3) 12 (33.3)
Histology
Well or Moderately
8 (32.0) 45 (43.7) 14 (38.9) 0.546
Poorly
17 (68.0) 58 (56.3) 22 (61.1)
Lymphatic invasion
No 14 (56.0) 8 (7.8) 7 (19.4) 0.0001
Yes 11 (44.0) 95 (92.2) 29 (80.6)
Venous invasion
No 19 (76.0) 56 (54.4) 18 (50.0) 0.085
Yes 6 (24.0) 47 (45.6) 18 (50.0)
Tumor stage
 25 (100) 44 (42.7) 9 (25.0) 0.0001
 0 59 (57.3) 27 (75.0)
Surgical Procedure
Distal 16 (64.0) 62 (60.2) 12 (33.3) 0.013
Total 9 (36.0) 41 (39.8) 24 (66.7)
Well well differentiated adenocarcinoma,Moderatelymoderately differenti-
ated adenocarcinoma, Poorly poorly differentiated adenocarcinoma,
Distal distal gasterectomy, Total total gastrectomy.
Values in the parenthesis are the percentages
Fig. 2. Survival curves among patients with tumors of stageor.
Significant differences were observed between the survival of patients
with cumulative scores of 0 and 1 (P = 0.0010) and those patients with
cumulative scores of 1 and 2 (P = 0.0004).
Table . Multivariate analysis to determine factors independently
correlated with patients’ prognosis
Variable Odds Ratio (95%confidence interval) P
Depth of tumor 5.00 (1.35 -18.5) 0.016
Cumulative score 3.70 (1.83 -7.52) 0.0003
Lymphatic invasion 2.37 (1.08 -6.06) 0.072
Venous invasion 1.39 (0.71 -2.72) 0.335
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the gastric carcinomas that have been treated with curative surgical
resection, lymph node metastasis, in both senses of their existence
(1) and the number (3, 9) and/or proportion (2) of the nodes in-
volved by the carcinoma cells, could be a representative indicator
for the biological potential of the tumors among these pathologic
elements.
As a prognostic indicator based on laboratory data, elevation of
serum C-reactive protein (CRP) has come to be used as an
indicator of patient outcome in some human malignant tumors of
the digestive tracts, including gastric carcinoma, both independ-
ently5 and by such combined forms as the Glasgow Prognostic
Score (GPS) (4, 10).
While the scope of these investigations might suggest that
criteria to determine patients’ prognosis in gastric carcinoma
based upon the combination of pathologic lymph node metasta-
sis, as a representative of tumor-related factors, and elevation of
serum CRP. as a representative of the host-related factors, ap-
pears to be much more useful, there has been no previous at-
tempt to produce such criteria for patients with gastric cancer
who had been treated with curative resection. Indeed, such at-
tempts to readily reconstruct the criteria to determine and predict
the prognosis of patients, based on both tumor-related and host
related factors, have been introduced regarding colorectal carci-
noma (11, 12).
Indeed, in the current study, the cumulative score system formed
by the combination of the presence of pathologic lymph node
metastasis and elevation of serum CRP could provide a strict
stratification of survival of patients with gastric carcinoma who
have been treated with curative resection. And a similar results
could be demonstrated in analysis restricted to patients with TNM
stageortumors. Moreover, this cumulative score proved to be
significant as an independent prognostic indicator of gastric carci-
noma.
It holds true that the most popular criteria to determine prog-
nosis in gastric cancer remains to be TNM staging system.
However, our score system can be composed of two factors and
simply classified to only three groups and the prognosis of the
group could be clearly divided with a strict stratification, being the
most outstanding advantage of our score system. And the most
outstanding significance in this study is to create staging system
based on both tumor-related and host-relates factors.
While determination of an existence of nodal metastasis might
be found by diagnostic images including computed tomography
(CT) and positron emission tomography (PET), our cumulative
score system would exert an ability also to preoperatively predict
the subsequent prognosis of the patients.
In conclusion, the cumulative score system generated by the
basic data of pathologic nodal metastasis and elevation of serum
CRP can be applied to the majority of the medical institutes and it
could be an easy and useful information to predict outcome of the
patients with gastric carcinoma that had been treated with curative
surgical treatment.
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